Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
about
Oral antineoplastic agents: how do we care about adherence?Impact of pharmacy channel on adherence to oral oncolytics.The use of erlotinib in daily practice: a study on adherence and patients' experiences.Oral anticancer agent medication adherence by outpatientsThe role of dasatinib in the management of chronic myeloid leukemiaMoving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient settingThe use of capecitabine in daily practice: a study on adherence and patients' experiencesImplementation of management guidelines for chronic myeloid leukemia: perspectives in the United States.A Systematic Review of Adherence to Oral Antineoplastic TherapiesMeasurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Adherence and patients' experiences with the use of oral anticancer agents.A review of economic impact of targeted oral anticancer medications.Insights on practice variations in the management of lymphoma and leukemia.Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation.Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
P2860
Q28082909-87EE139E-CA69-4778-9FA4-8050DD25ED7EQ33815415-1E716805-EDED-4F90-8CE8-ECE9C2E408CCQ33948681-3B878C0A-AA29-4077-ACD6-78370FF96374Q34293339-98E96BE3-7504-478D-81D5-98F2CC633902Q35087994-D917BF78-31D9-4B6A-A790-3F1D931989FCQ35117747-1256E9C3-39BC-4A1E-8270-C677E430C755Q35742246-B59B0DC3-DBD8-4C75-8485-85B0C8C043A3Q36358178-47D47404-9706-4877-81C1-6772619A9477Q36401763-91B9C9CC-227C-4E77-B24D-22094C550D0DQ36673490-3ACDE177-E04D-4E14-BD7A-EE64C2C9835EQ37618888-56585123-C037-492E-9EF0-D86D2E4A0C37Q37998410-EF910FB7-1B23-46D7-986B-3B3FCD1DF1DBQ37999726-944C2298-42B5-4B38-BF69-54E80AE3003EQ38165220-DF84D2D6-D057-4FD5-BDDA-A8E31FB6117CQ38174702-967FD837-F556-4207-9BF1-7EA8211F2BC4Q38177354-A3910C0F-2CC0-48FE-8790-B00A1DEFD317Q38356369-1867B38A-A6BF-4800-9B9D-2F3622559184Q41729314-B6B84C3E-335C-4B1D-A8A8-963DE3B26DBCQ46641199-0811001F-EEAA-4C8B-976E-1A0581AFA395Q50128334-C28EC688-4F5A-43DB-86F5-F3AD5D822D0C
P2860
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@en
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@nl
type
label
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@en
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@nl
prefLabel
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@en
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@nl
P2093
P1476
Retrospective real-world compa ...... b in chronic myeloid leukemia.
@en
P2093
Andrew P Yu
James D Griffin
Vamsi K Bollu
P304
P356
10.1185/03007995.2010.533648
P407
P577
2010-11-09T00:00:00Z